Showing results (341-350 of 447) with videos related to

Sort By:
Pageof 45
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Data in Brief|November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitisLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2026
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experienceFrancis Proulx-Rocray, Rebecca Symons, Yang Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort studyLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Urology Focus|February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted TherapyPeter E Hall, Scott T C Shepherd, Janet Brown, et al.
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
Clinical Kidney Journal|June 3, 2026
Environmental footprint of peritoneal dialysis in Europe: a comparative life cycle assessment across four European centresAbass Fehintola, Zuzanna Jakubowska, Malgorzata Kepska-Dzilinska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 TrialMehmet A Bilen, Brian I Rini, Martin H Voss, et al.
The Lancet. Oncology|April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Pageof 45